Superlab Suisse, a leading provider of innovative laboratory and research spaces, has announced the grand opening of its latest facility in Basel. This new establishment makes Superlab Suisse the largest private lab space provider in Switzerland, adding a significant asset to the life sciences sector. Opening in July 2024, the Basel facility follows the successful Lausanne location, supported by Biopôle Lausanne and InnoVaud.
The expansion to Basel, a burgeoning biotechnology hub home to over 700 companies including pharmaceutical giants like Novartis and Roche, marks a major milestone. The facility is located in Stücki Park, surrounded by notable neighbors such as Tech Park Basel, Lonza, Medartis, NBE, and Boehringer Ingelheim. This prime location offers ready-to-use laboratory spaces equipped with the latest technology and essential operational support services, enabling research teams to focus on scientific discovery rather than lab operations.
Spanning over 4770 square meters, the new facility promises to be a hub for scientific collaboration and innovation. "We are thrilled to bring Superlab Suisse's innovative platform to Basel, the city of Pharma," says Xi Zhang, CEO of Superlab Suisse. "Our holistic solution frees scientists from operations headaches, so they can save time and focus on science. We service, you discover."
Historically, life sciences and biotech companies have struggled with the financial burden of building and operating lab spaces, often diverting valuable resources away from research. Superlab Suisse's serviced BSL1 and BSL2 labs set a new industry standard, providing a viable alternative to the traditional university-based lab solutions. These facilities are designed to be move-in ready, eliminating the hurdles of lab construction and operation, and are accessible to companies of all sizes, including startups, scale-ups, and corporates.
One of the first companies to secure their space at the new facility is Skyhawk Therapeutics, which recently announced a research collaboration with Ipsen focusing on RNA targeting in rare neurological diseases. The Basel location is part of Superlab Suisse's broader commitment to innovation, with plans for a third site in Zurich Schlieren scheduled to open in March 2025. This forthcoming facility will cater to the diverse needs of start-ups, spin-offs, and established companies in the life sciences sector, further solidifying Superlab Suisse's position as a leader in laboratory-as-a-service solutions.
Superlab Suisse's one-stop solution not only addresses the critical challenges faced by life science companies but also fosters a collaborative environment for like-minded innovators. The company is expanding its footprint to more cities in Europe, the US, and Asia, embodying a borderless lab concept to advance life sciences globally.
Dr. Rajwinder Lehal, CEO of biotech business Cellestia, remarked, "Superlab is exactly the place which the scientific community needs, where we can concentrate on our work without being distracted by construction or operation. Superlab provided us with state-of-the-art infrastructure and equipment that we needed to hit the ground running from day one." Emmanuel Savioz, CEO & Chairman of Tigen Pharma, added, "Superlab is a great place to work in a vibrant scientific community. Our team at Tigen can focus on growth, supported by state-of-the-art facilities, latest equipment and a competent and fun Superlab team to support on-site."
